Jefferies on Viridian Therapeutic (VRDN): bears to argue commercial oppy not clean, bulls see de-risk
Tweet Send to a Friend
Jefferies analyst Faisal Khurshid reiterated a Buy rating and $45.00 price target on Viridian Therapeutic (NASDAQ: VRDN)The analyst commented, "Topline ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
